文献速递系统性红斑狼疮

系统性红斑狼疮缓解定义评估:一项前瞻性队列研究

Evaluation of remission definitions for systemic lupus erythematosus: a prospective cohort study.
PubMed 文献 · Lancet Rheumatol · 2019-09-25

结果显示,达到缓解与损伤累积和复发显著减少相关;LLDAS比任何缓解定义更易达到,且保护作用相似。

要点

  • 观察时间≥50%处于任何缓解状态与损伤累积显著减少相关,但两个最严格定义例外。
  • LLDAS比任何缓解定义更易达到,且对损伤和复发的保护作用相似。

核心结论

  • 达到缓解与不可逆器官损伤累积和疾病复发的显著减少相关。
  • LLDAS比基于DORIS标准的缓解更易实现,但保护作用相似。
  • 严格程度较低的缓解定义可能与LLDAS区分不足,需进一步研究区分各缓解定义的保护效应。

研究设计与样本

  • 纳入标准为年龄>18岁且符合1997年ACR或2012年SLICC的SLE分类标准。
  • 评估8种DORIS缓解定义(在血清学活动性、糖皮质激素使用和免疫抑制剂使用方面不同)及LLDAS的达成情况,每年记录不可逆器官损伤累积。
  • 主要目标为评估各缓解定义或LLDAS的暴露与不可逆器官损伤累积的关联,疾病复发为关键次要结局。
  • 使用时间依赖Cox比例风险模型和广义线性模型评估关联。

主要发现

  • 观察时间≥50%处于任何缓解状态与损伤累积显著减少相关,但两个最严格缓解定义(达成频率最低)例外。
  • 不允许血清学活动的缓解定义与疾病复发减少的关联最大。
  • LLDAS比任何缓解定义更易达到,且与损伤累积和疾病复发的保护程度相似。
  • 在达到LLDAS但未达到缓解的患者中,LLDAS与损伤累积减少显著相关,独立于所有缓解定义(除最不严格者外)。

关键数值与推荐

  • DORIS缓解定义共8种,在血清学活动性、糖皮质激素使用和免疫抑制剂使用方面不同。
  • 观察时间≥50%处于缓解状态与损伤累积显著减少相关(除两个最严格定义外)。

临床怎么用

  • 在SLE临床管理中,达到缓解或LLDAS均应作为治疗目标,以降低器官损伤和复发风险。
  • LLDAS比DORIS缓解定义更易实现,可作为更实用的治疗目标。
  • 选择缓解定义时需注意严格程度,过于严格的定义可能难以达成且保护效应不明显。

局限性

  • 研究为观察性设计,不能确立因果关系。
  • 部分缓解定义达成频率低,可能影响统计效力。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: Validated outcome measures are needed from which to derive treatment strategies for systemic lupus erythematosus (SLE). However, no definition of remission for SLE has been widely adopted. The Definitions of Remission in Systemic Lupus Erythematosus (DORIS) group has proposed a framework with multiple potential definitions of remission. In this study, we aimed to assess the attainability and effect on disease outcomes of the DORIS definitions of remission, compared with the lupus low disease activity state (LLDAS), in patients with SLE. METHODS: In this prospective cohort study, we enrolled patients with SLE from 13 international centres that are part of the Asia Pacific Lupus Collaboration. Eligible patients were older than 18 years and fulfilled one of two classification criteria for SLE (1997 American College of Rheumatology criteria or the 2012 Systemic Lupus International Collaborating Clinics criteria). Visits were according to clinical need, with a minimum frequency of one visit per 6 months. We assessed attainment of remission on the basis of the eight DORIS definitions of remission, which varied in terms of serological activity, glucocorticoid use, and use of immunosuppresive agents; attainment of LLDAS; and disease flares at each visit. Irreversible organ damage accrual was recorded annually. Our primary aim was to assess exposure of patients to each of the remission definitions or LLDAS, and the respective association of these states with accrual of irreversible organ damage as the primary outcome measure. Occurrence of disease flares was the key secondary outcome. We used time-dependent Cox proportional hazards models and generalised linear models to assess DORIS definitions of remission and LLDAS in terms of their association with damage accrual and disease flares. FINDINGS: Between May 1, 2013, and Dec 31, 2016, 1707 patients with SLE were recruited and followed for a mean of 2·2 years (SD 0·9), totalling 12 689 visits. Remission, depending on DORIS definition, was achieved in 581 (4·6%) to 4546 (35·8%) of 12 689 visits. Spending 50% or more of observed time in any remission state was associated with a significant reduction in damage accrual, except for the two most stringent remission definitions, for which the frequency of attainment was lowest. Remission definitions disallowing serological activity were associated with the greatest reductions in disease flares. LLDAS was more attainable than any remission definition and was associated with a similar magnitude of protection from damage accrual and disease flares. Sustained remission and LLDAS were associated with a wider spread of effect sizes for reduction in risk of damage. By analysing patients who met the definition for LLDAS but not remission, we found that LLDAS was significantly associated with reduction in damage accrual, independent of all definitions of remission, except the least stringent. INTERPRETATION: Attainment of remission was associated with significant reductions in damage accrual and disease flares. LLDAS was more achievable than remission based on the DORIS criteria, but was similarly protective. Remission definitions with less stringency might be insufficiently distinct from LLDAS to substantially affect outcome measures, and further studies are needed to distinguish the protective effects of the various remission definitions. FUNDING: UCB, GlaxoSmithKline, Janssen, Bristol-Myers Squibb, and AstraZeneca.

来源:Lancet Rheumatol,查看原文。版权归原作者所有。

引用

  1. Golder V, Kandane-Rathnayake R, Huq M, et al. Evaluation of remission definitions for systemic lupus erythematosus: a prospective cohort study. Lancet Rheumatol. 2019. PMID: 38229337. doi:10.1016/S2665-9913(19)30048-7

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。